0001104659-23-086578.txt : 20230802 0001104659-23-086578.hdr.sgml : 20230802 20230802070521 ACCESSION NUMBER: 0001104659-23-086578 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230802 ITEM INFORMATION: Other Events FILED AS OF DATE: 20230802 DATE AS OF CHANGE: 20230802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MedTech Acquisition Corp CENTRAL INDEX KEY: 0001826667 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 853009869 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39813 FILM NUMBER: 231133697 BUSINESS ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 6462096063 MAIL ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 8-K 1 tm2322654d1_8k.htm FORM 8-K
0001826667 false 0001826667 2023-08-02 2023-08-02 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-08-02 2023-08-02 0001826667 us-gaap:CommonClassAMember 2023-08-02 2023-08-02 0001826667 us-gaap:WarrantMember 2023-08-02 2023-08-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 2, 2023

 

MedTech Acquisition Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   001-39813   85-3009869
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

48 Maple Avenue,
Greenwich, CT		   06830
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 391-1288

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on
which registered
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant   MTACU   The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share   MTAC   The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share   MTACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

 

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously reported, on November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“MTAC” or the “Company”), entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“Merger Sub”), and TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “Merger”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock (the transactions contemplated by the Merger Agreement and the related ancillary agreements, the “Business Combination”). Upon consummation of the Business Combination, MTAC will be renamed “TriSalus Life Sciences, Inc.” In connection with the Business Combination, MTAC filed a registration statement on Form S-4 (File No. 333-269138) (as amended, the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”). On July 18, 2023, the Registration Statement was declared effective by the SEC and on July 18, 2023, MTAC filed a Definitive Proxy Statement/Prospectus (the “Definitive Proxy Statement/Prospectus”) relating to MTAC’s special meeting (the “Special Meeting”) scheduled to be held on August 2, 2023, to among other things, obtain the approvals required to consummate the Business Combination.

 

Since the filing of the Definitive Proxy Statement/Prospectus, TriSalus received written responses from the U.S. Food and Drug Administration (“FDA”) in reference to a Type B meeting request for TriSalus’ PERIO-01 clinical program. MTAC is including in this Current Report on Form 8-K certain supplemental disclosures that amend and supplement the Definitive Proxy Statement/Prospectus in connection with such written responses.

 

SUPPLEMENT TO DEFINITIVE PROXY STATEMENT/PROSPECTUS

 

This supplemental information should be read in conjunction with the Definitive Proxy Statement/Prospectus, which should be read in its entirety and is available free of charge on the Internet site maintained by the SEC at http://www.sec.gov. The supplemental information below supplements and updates the information set forth in the section entitled “TriSalus’ Business” in the Definitive Proxy Statement/Prospectus. Defined terms used but not defined herein have the meanings set forth in the Definitive Proxy Statement/Prospectus. To the extent the following information differs from or conflicts with the information contained in the Definitive Proxy Statement/Prospectus, the information set forth below shall be deemed to supersede the respective information in the Definitive Proxy Statement/Prospectus.

 

On July 31, 2023, TriSalus received written responses (“FDA Responses”) from the FDA in reference to a Type B meeting request for TriSalus’ PERIO-01 clinical program. The FDA acknowledged that preliminary data from the PERIO-01 program suggests a tolerable safety profile of SD-101 delivered by TriSalus’ pressure-enabled drug delivery (“PEDD”) method in combination with systemic checkpoint inhibition in metastatic uveal melanoma patients, and that there were no concerns raised with respect to delivery of SD-101 via PEDD with the TriNav device. The FDA has asked for additional exploration of the optimal SD-101 dose, in a smaller study prior to proceeding with a registrational trial. TriSalus currently expects to have Phase 1 more mature efficacy data at the multiple SD-101 doses for its PERIO-01 clinical trial in the second half of 2023. Based on the FDA’s feedback, TriSalus will move forward with a 40-50 patient study to generate additional efficacy data to determine the optimal SD-101 dose for the PERIO-01 program. TriSalus plans to initiate the Phase 2 trial for its PERIO-01 program to generate the additional efficacy and dose optimization data in 2023; however, the initiation and timing of such Phase 2 trials and related data milestones are subject to change and dependent on multiple factors, including interactions with regulatory authorities, enrollment rates, and external events which may impact operations at clinical sites. As a further result of the FDA Responses, TriSalus anticipates that a potential new drug application submission with respect to SD-101 in uveal melanoma with liver metastases is likely to occur beyond 2025, pending Phase 2 efficacy and dose optimization data.

 

 

 

 

In connection with its development plan for hepatocellular carcinoma (“HCC”), TriSalus is also considering a separate study for advanced second line and beyond HCC with SD-101 in combination with Y90 radioembolization. HCC study prioritization will be based on data expected to be available in the second half of 2023.

 

Special Meeting

 

As previously reported, the Special Meeting is scheduled to be held at 11:00 a.m. Eastern Time, on August 2, 2023, which will be conducted exclusively over the Internet by means of a live video webcast, which can be accessed by visiting https://www.cstproxy.com/medtechacquisition/sm2023, unless the Special Meeting is adjourned. The purpose of the Special Meeting is to vote on certain proposals related to the Merger Agreement and the proposed Business Combination. All information about the Special Meeting, including the Definitive Proxy Statement/Prospectus, is available at https://​www.cstproxy.com/medtechacquisition/sm2023.

 

Additional Information

 

In connection with the Merger Agreement and the proposed Business Combination, the Company filed the Registration Statement with the SEC, which includes a proxy statement/prospectus of the Company that will be both the proxy statement to be distributed to holders of the common stock in connection with its solicitation of proxies for the vote by the Company’s stockholders with respect to the Business Combination and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the Business Combination. On July 17, 2023, MTAC mailed the Definitive Proxy Statement/Prospectus to the MTAC stockholders as of the close of business on July 3, 2023, which is the record date established in connection with MTAC’s solicitation of proxies for the vote on the Business Combination and related matters to be presented at the Special Meeting. The Company’s stockholders and other interested persons are advised to carefully read the Definitive Proxy Statement/Prospectus, any amendments or supplements thereto, as well as any other documents filed with the SEC because they will contain important information about MTAC, TriSalus and the Business Combination. The Company’s stockholders and other interested persons may obtain free copies of the Definitive Proxy Statement/Prospectus and other documents filed with the SEC by MTAC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by the Company can be obtained free of charge by directing a written request to MedTech Acquisition Corporation at 48 Maple Avenue, Greenwich, CT 06830.

 

Participation in Solicitation

 

The Company and TriSalus and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of the Company’s stockholders in connection with the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of the Company’s directors and officers in the Company’s filings with the SEC, including the Company’s registration statement on Form S-1, which was originally filed with the SEC on November 30, 2020, as amended, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 22, 2023, and the Definitive Proxy Statement/Prospectus. To the extent that holdings of the Company’s securities have changed from the amounts reported in the Definitive Proxy Statement/Prospectus, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from the Company’s stockholders in connection with the Business Combination are included in the Definitive Proxy Statement/Prospectus. Investors and security holders of the Company and TriSalus are urged to carefully read in their entirety the Definitive Proxy Statement/Prospectus and other relevant documents that will be filed with the SEC, when they become available, because they will contain important information about the Business Combination.

 

 

 

 

Investors and security holders will be able to obtain free copies of the Definitive Proxy Statement/Prospectus and other documents containing important information about the Company and TriSalus through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by the Company can be obtained free of charge by directing a written request to MedTech Acquisition Corporation at 48 Maple Avenue, Greenwich, CT 06830.

 

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING THEREOF OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

  

Forward-Looking Statements

 

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the United States federal securities laws regarding the Company’s or TriSalus’ expectations, hopes, beliefs, assumptions, intentions or strategies regarding the future including, without limitation, statements regarding the anticipated timing of the Special Meeting and the completion of the Business Combination. These forward-looking statements generally are identified by words such as “intend,” “may,” “plan,” “will” and similar expressions or the negative or other variations of such statements. These statements are predictions, projections and other statements about future events that are based on various assumptions, whether or not identified in this Current Report on Form 8-K and on the current expectations of the Company’s and TriSalus’ respective managements and are not predictions of actual performance and, as a result, are subject to risks and uncertainties.

 

Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of the Company’s securities; (ii) the risk that the Business Combination may not be completed by the Company’s business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Business Combination, including the approval of the Merger Agreement by the stockholders of the Company, the satisfaction of the minimum cash amount following any redemptions by the Company’s public stockholders, and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party valuation in determining whether or not to pursue the Business Combination on the terms set forth in the Merger Agreement; (v) the failure to satisfy the conditions to the consummation of the private placement of a to-be-authorized class of preferred stock, par value $0.0001 per share, that will be designated as Series A Convertible Stock to close concurrently with the Business Combination and the resulting impact on the amount of capital available to the Company at the potential closing of the Business Combination; (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vii) the receipt of an unsolicited offer from another party for an alternative transaction that could interfere with the Business Combination; (viii) the effect of the announcement or pendency of the Business Combination on TriSalus’ business relationships, operating results and business generally; (ix) the risk that the Business Combination disrupts current plans and operations of TriSalus; (x) the outcome of any legal proceedings that may be instituted against TriSalus or the Company related to the Merger Agreement or the Business Combination; (xi) the ability to maintain the listing of the Company’s securities on the Nasdaq; (xii) changes in business, market, financial, political and legal conditions; (xiii) unfavorable changes in the reimbursement environment for TriSalus’ products; (xiv) the ability of the Company or the combined company to raise additional financing in connection with the Business Combination or to finance its operations in the future; (xv) the ability to implement business plans, forecasts and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; (xvi) TriSalus’ expectations for the timing and results of data from clinical trials and regulatory approval applications; (xvii) costs related to the Business Combination; (xviii) the failure to realize the anticipated benefits of the Business Combination or to realize estimated pro forma results and the underlying assumptions, including with respect to estimated stockholder redemptions; and (xix) other risks and uncertainties indicated from time to time in the Registration Statement, including those under the “Risk Factors” section therein and in the Company’s other filings with the SEC. The foregoing list of factors is not exclusive.

 

 

 

 

The Company’s other SEC filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and none of the Company, TriSalus, or any of their respective representatives assume any obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of the Company, TriSalus, or any of their respective representatives gives any assurance that either the Company or TriSalus will achieve its expectations.

 

No Offer or Solicitation

 

This Current Report on Form 8-K shall not constitute an offer to sell, a solicitation of an offer to buy or a recommendation to purchase any securities, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Business Combination, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdictions. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MedTech Acquisition Corporation
   
Dated: August 2, 2023 By: /s/ Christopher C. Dewey
    Name: Christopher C. Dewey
    Title: Chief Executive Officer

 

 

 

 EX-101.SCH 2 mtac-20230802.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 mtac-20230802_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 mtac-20230802_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member] Common Class A [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant EX-101.PRE 5 mtac-20230802_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 02, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 02, 2023
Entity File Number 001-39813
Entity Registrant Name MedTech Acquisition Corporation
Entity Central Index Key 0001826667
Entity Tax Identification Number 85-3009869
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 48 Maple Avenue
Entity Address, City or Town Greenwich
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06830
City Area Code 908
Local Phone Number 391-1288
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant
Trading Symbol MTACU
Security Exchange Name NASDAQ
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol MTAC
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol MTACW
Security Exchange Name NASDAQ
XML 7 tm2322654d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001826667 2023-08-02 2023-08-02 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-08-02 2023-08-02 0001826667 us-gaap:CommonClassAMember 2023-08-02 2023-08-02 0001826667 us-gaap:WarrantMember 2023-08-02 2023-08-02 iso4217:USD shares iso4217:USD shares 0001826667 false 8-K 2023-08-02 MedTech Acquisition Corporation DE 001-39813 85-3009869 48 Maple Avenue Greenwich CT 06830 908 391-1288 true false false false Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant MTACU NASDAQ Class A common stock, par value $0.0001 per share MTAC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share MTACW NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6 M,P$ "(" / " 9(1 !X;"]W;W)K8F]O:RYX;6Q02P$" M% ,4 " "J. )7)!Z;HJT #X 0 &@ @ 'R$@ >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "J. )799!YDAD! M #/ P $P @ '7$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" A%0 ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://medtechacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2322654d1_8k.htm mtac-20230802.xsd mtac-20230802_def.xml mtac-20230802_lab.xml mtac-20230802_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2322654d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "mtac-20230802_def.xml" ] }, "inline": { "local": [ "tm2322654d1_8k.htm" ] }, "labelLink": { "local": [ "mtac-20230802_lab.xml" ] }, "presentationLink": { "local": [ "mtac-20230802_pre.xml" ] }, "schema": { "local": [ "mtac-20230802.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 1, "memberStandard": 2, "nsprefix": "MTAC", "nsuri": "http://medtechacquisitioncorp.com/20230802", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2322654d1_8k.htm", "contextRef": "AsOf2023-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://medtechacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2322654d1_8k.htm", "contextRef": "AsOf2023-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "MTAC_UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant", "label": "Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember", "nsuri": "http://medtechacquisitioncorp.com/20230802", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-086578-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-086578-xbrl.zip M4$L#!!0 ( *HX E?GI8#(X@, (H. 1 ;71A8RTR,#(S,#@P,BYX M(CAV485#"NSU>E^V-)H>4%DC84EC M<+X^K;E@[@LDGB>I=4Y?I.Z6IO5EG@CR MIP)=M>K5+U"$BF(B[';>]^Y'=& MW5[/(U\N?_V%X-?ZS??)-0<1-@25F&02SV:PBU0N= M*?UD*DPEARD<66I3L]!6G5>+[S#Z+3=L03ZCG?/9[_,A_S8&^2GMT\9W]D ? M;L["0?3/]^$9?WR:V^2/6?@@G^7K!W.O'N/&J/$8"),8^F&0FVP9-H&$$CP, M:=J>BZ\(;]:H*#T.ZM5J+?AVVQ]E."\'-N>"RZ=M\-K%Q460K9;0#>0\U*)4 MW0C<=;H+4@*1!3:A[#GEAENL%:;TU.5V9JWZJ5K'"A60 M@+372B=7$--48$#/*14\YA!YQ%(]!NN2U4PI@Z-TE_E/I518)H@I)$XVG7*L M@X4 12YOFEH)N,/8B!M@G1YBT$&#KL+.XQ$>M;U\N*2Z5!Y!S&7&O2RJM$9\ M5Y.IVP(<9LQ6L [>U)0:B ;R,AM/-1BD9P'V45#P"\A^+J."I>(DZIM_^YB% MO-S6C?TNBW4(,"3X'R,7-#PV M,>0^T[_>\2*679LK*N)^4X!7RV,;$;="E:["\[7.U + U?:$KG1V/;= M3_G-VEXUNY00@K"DE)[NP?#?_!Q\R-4TTWEY5AQU$B<\/P3VT3C5[0A9L&M^9 L4#+'NYN.?;CWOL M:^9/RB9=)0TW%G^?!O% PFA"-0SBKJ#&=/ W*%%R9!5[ZDB\\N%NPG64X880 M ;H8"GB@6E-I;R$)W=O(18D_8N^EGH;&:LKP_6AUBHU*7&ULU5U=4^,X%GV?JOT/WLQS"(%A=F":G4JG82HUW0U+Z.[= M?:$46TE4R!(CR9#\^Y7\$?RA:SN]($8\0&)?2>>>(U_IVI)Y]]LFIL$C%I)P M=CX8'QP. LQ"'A&V.A]\F0\G\^EL-@BD0BQ"E#-\/F!\\-L___9#H'_>_7TX M#"X)IM%9\(&'PQE;\E^#SRC&9\'OF&&!%!>_!E\13GI@/%'],3%O3P(>=RO MPKE"*I&[V@XWA_E/5OP=)>S^S/Q:((D#S1>39QM)S@>FW;S9I^,#+E:CH\/# M\>C?GS[.PS6.T9 PPUN(!T4I4XNMW/CT]'24GBU,&Y:;A:!%&\>C LZN9GTV M4KL"9>.347:R;$I:JBZ!EN1,IIY\Y"%2:0_I1!2 %N;;L# ;FD/#\='P>'RP MD=&@T"DE6W"*;_ R,'^UT+M68QPI'*Y1^&=")#& 0BX>C-(C8SJ:ZT MDK7 R_-!K%"HVSHZ/OSE\,BT]&/%2&T?=(^6Q'3(03"JH$ B+(#8C,NM #X7 MU!MG3]+&U[H*$28+/(Q(C)GI_(,@;ZCLZ:X6PM1(FXYRFY&U@M?'O6ML&/$8 MD3U!-TL[0)RV-(QQO#!R[P6W6O3UL2)*]T.8%GA]7(RKR;[0BC).^R1>HH2J M[^Z41?$J9GV8L#3*?-1?*[CQ1NE1"$<%VS\!-1X,Y[3<]+,^NJ9R%G2G>5"YJVIKL[7ID/ M!;*EX'%/0G/R>*L?988UG$' 182%GM4=/B.B7.+H?*!$8G'5#SKZ%H7JYU]0"+(5XM:;Z5+&>*'?)R&!+'9OJ@2S2E# MEPP@P[P3.23%T:&?6MR-+K=BE;=/DKL=]$"\;)%R&^?V9QJVMLSR2, MQ=V)8X+WG'C;X$(,O\CWQ/\K04)A0;=]N*\9>T2_#3FDP(GCR8R>9&5W M=OM(4+?V2 ,K=$B$G]V*,%]C2LVC9,1Z70E->X^$ ,!#4OSC[:2X>#33"#U> M]5=C5\130:KX(4U^<:O)-1:$1WKF('JH43/V2 <;4'&? IMH3@>B,17CS!]ZV45\S]89[ M&VZ0?$=)<8;L6I 8B>V\="=]RA-]!6^G/&H=&EH+>B-0MQ>@3([RY0SG M)(H$EC+_8_P:MXEC,?=&$@@[^+#-4>X,H3O:3X@CCX4X:A?"4>X,H3O>3XAC MCX4X;A?"409=03?5'Z_$+7\"GOT#QKZ)4$,.2N T?/7E;@6_)%D6]2Z M=*B5\$T,&WQ0$:A_R4/7/-9F M[YL*3?"@%HXR[KQ?F!LQT&*PBHD'C#?Q@B0[2JO-6#01&,%=O&SA \5UN"## MCG+DC]P\.UISUGIWNF[E =-6R"#;KE)=LV]4@@%C=]H#?JM8(6*_>SO.GL1^ M$T1I/&;W0<+R.U' LT:KJ0>$P[A!\AVEJW-.24C,OIU/>K8J"*)VYIMV'M . M@ 8Y=Y297@ML>@+624&Z4,]L1Q=7RR44P6%[#S3H ]JX2A%K<&;29E@L:\B MC5+^Z6)W 53'4;HZQV&B0^=V?+2X-2]; &)3SE&0Q](!S"#5(NZ-LM(+*3GC%Q .JFWA!DAUEH\4%=[$)UXBM,+RV MQ&;I >4@;)!Y1UGJ4I1:@LHT&9CO^@I(5@G<]MA3P M2 ,(/23'3ZYV^*;[T$K.7.H/=B&LIAY( .,&R7>U]3>)B,)1!O"2,,1"G0+N M-F0"]QBZ2OD@21\70'6R8"%/% EV[\H"A. MG]A^Y31A"HET@; KA.KJ3*-("'U3$Z6+I]**=ZN%LQ=O7+U0,O>&_ MB1JDW>D:Z7F,*'V?2.V ;(U(%4-O:&^B!FEWN@KZ(L9BI0/C[X(_J76^<;F- M?FL!;V2 T8-R.%WM?+%Y?K5"MG.S58N&M3]"V*%#*MC<>@T5=N]X"4.SZ"6; M,; ("4 'V-X#)3K @UHX2K&OU!J+\LPMA6:<:5N2TE7* UUZN0"JXS3%+K_N MHG70+MEYH &N3<:09]G2PH"2\I1ZUY0LG,&\;KF$'"G6;-[Q&[%\F#"K?7 M@H<8F\=/E7@C4C]O0'E<[OU^/D5P>FK@^55HM+_6Z31MM[Z:"GG MC5B=3H :.7YMEWS>D(BC]]L;O,3"+""YQ1OU7C=TWSX!ZRSN@6+[^0(*5TK; MWXUJ;NKF[_6Y_+CY9?[IDC[R/U!+ P04 " "J. )7GO8]F_P%5O[0SD>7+ MM%-[D]U1%'O'LTGL6G+2-M/)0"0D<4P!'I#RY=\7%Y(B01R2]C8 ]D-6)M\# MO" > B!%'KW]Y6F;H@?"LX31=Z.C@\,1(C1B<4+7[T:W\_%T/KN\'*$LQS3& M*:/DW8BRT2\___$/2/SW]D_C,;I(2!J?H0\L&E_2%?L)?<9;7%;E;O+\ M/CN;3!X?'P\H>\"/C-]E!Q';#BMPGN-\EU6E'3X=%O_I\+=I0N_.Y#]+G!$D MCA?-SIZRY-U(UEM4^WARP/AZ#3YUZ>/\VA#MGB<4'G<(C(JHV0IMKBC MT]/3B=I;2EO*IR5/RSI.)J6=JF2Q-^G0UYQDR5FF['UD$'QR=/"4Q:/RX*LCR%E*;L@*J6:>Y<_W J4LD22,BFT;3E9V,RGG M$QD_H62-TUXPN)S M^CK79K0G^^+E0CWXT&Z"=F V3DE)>MP#SJ.12%8A(Q,9'=Y^-4'W0= MON)L.\A&<3?=&O86F;XT@!'&D?BQ5;E T\7!DE3_R'J\GQ .&F>>2ZJV-XB(^E!452A/+G$Q MA#)9I_Q#GW)3(9'UBNLE>>*):R:I&N>R[C)D7STJZD??M(/??8K^[N%>'S5] M!*WG89?0Y0 /&ZV/[&V5=X)[K;7&<@U4R5BXEA6 M?I'BM<6^L=]5%UMME7WKF#R2+>'(OQY6N=C1DSCO= M8K+5]S5-6 BTC<$DU+2>!O8;LA:7SEQ---6*I6,8 _2NA_Y.V^9<8!4' R(R*0$5( M.-B\3GI;M+GXJ<; (F0X'4J3"D(SS1%+MP:@>AEI*U_0 M5DUN#%E0Q-B]@:QH.5)Z_Y"A2A .)K.^M 0:I]@7"19 MA%/MY4)LZ_H&QJ)U#0AHUX2D)0P*%,@="(L.*)E1(5Z!^3?!?!@N-:4?6%I6 M[:A4L@!!,;WU82+U7B"9[3AON(9G'%CJ"I,^LR4GD"X(4'K,M9X.TO(&*)YF MH'.:)_FS?,/G\\[R3)!=XHH-R%S)A+D_"!8 4R8#6H:D#FFAEYXOOR6@N7RM M"FR.*7-+@-UDDX*F)B 2K,8 &O9:]9:;%R)F8F3B.+VD,7GZC3R#[6KIW#(! MV&Q"88@"HL+N#,"B$".E1D+N!8QKGFPQ?YXG4<]4T1:Z10,RVF3#5 4$!V - MH*-0H_GES.=,LL!/E[$ -5DE^@W5'DI O5M8>FPWF0'$ :'3[1 @2 2A9I1/ MD"YIQ/@]JSWN,&,[,0 ^SU@,KU!ZHMQ"-:@)3;0Z0P(";(A/ +-&Z!O]3 IB M,K. *@#)$KP0-XUC<:"RXG\?$TJ.P/9;M6[IZK#;9,HB#(@DV!W 3Z%\4WY M,@9=T5"@.7Y!4X_]0W,\%)KCH*$Y?@TTBT<6"#0G+VCJB7]H3H9"O M@D9TO->Q9B8^7O$%>[0]G TJO2#3MFH%9B\+#Y>6MSY89(!KUA%'Y H"UQU=.0N;*WS?U! M]#A@RNQU)4-*Y^ENO,QYE]F'[]H^9S.[::>:R,L=0?2NZ:8U39?['??F5Y[D MHF:9F&A'BV]Y;,\- CI7O=QIL^QQJRB(WN]RULH(I+6H*7:,Q9RE293(Y&B? MQ,4G3["M53:1*R!@@R4-;440*("V6IF *B$JE8XAN.9$0DA$1ZB7 &6J4WZU M6EEG^RZQ*RCZ#9=PP,H@(.FU9\(B L91+0+I$*1B_&)SF64[PE\$CR7$$T*@ M>0"DECY$G""3O5#I0)]LS4FT$_/C\]'QO=/C'38[OYT P@#@*G(0Z!1V=D MT/A.1J$RK+@3YH6D+RS=T1QS]2XYMXU,@,XM.8#-)C&&*"!2[,X 0BHQTFH_ M+VCK[!'5(DO_$BK80$CN^'7M3M/&6]M6;4#,=!J$WN$N)8UH6V[EC*DE >-A\=620X:C4>F%AOL5I^GZ7)91D\$1DJ-RR M8+789*$A"8@%FR^ !25%I=8+"^=;PM=B>ON5L\=\4^1G!=L&J-VRT6FYR8A5 M&A K7?X 9LH0I&/*E+I^X'G:)Q3761;AEEJDCK$!S1K,M'0A 0.9:]&2DDC> M;_G,OXY0)^5MZX-L._2&N"!IJON2H3Q\$ M30--FDRIL.;%M0I4OXOH,YM1/;D]O,1KB!ROC"T&C85Q31$$(Z M:%E<_ZT M/[GS=LLTB2Y2AN&[+ V-XXQY;7M&LKR](" "VJZ@%'E*B)322_^_Q_2.[^[S MZ/F:LX@0^9155HU6????!D:[9>9%36K2-"@T(,Y>XA<@<%\$JI7QIC9C^;R9 MIW^N?IZSZ&Z^P>( 7NWR3,Z@PAA\%[PSR/'7"P,:8'S)T!$1$'H#;$)?.*A( MI$+?(!V,:M&>KL^R?19 $K]_OB$KPN5[!PORE+\7%=UU7&$,B'5]]3:X.>;% M7&]@$!"^U"UTJ9>A>@%H*9\1*XI WV0A2)72^?OE/Z G/RVFL^^W-,FS=5M=4:).F:O5+,59-JV=AU,:B[V+3<)CI;LA,2%;O$S)5\QE[NY/ MQ+SZ^I'U?(]9Y(R3N.A/VT.8#AIIXJ5J>X.(J ]%587RP57YUGPFZY1_J%K1 MM#$D(C$*2M4XEW67(?OJ45&_A&L+5F@[;:7'F$+T(DL,4E.X+^?9&," MV)*_I"W2^I 2WPVV]"Z66\J+3>7AX.&'\'CUP<2=/8I["*APKI#*YK:V[ZF[^%<5?4,+N M+LR/*9(XTGHQ>;&2Y+)EVMTT^W!VPL6\<]KM]CI_O7TSCA=_-L26D&NIH*6;9QURG"V->MOB0._$XDD%S(/[PV/D^JX\TH6 L\N6ZE"L6[K]*S[2_?4M/3]'DBME[J;2F)Z M62OJ[$6Q%%ABIG+B;_2!O2)XI73GPDE9D6G_>7$JHDS134?J16W3Z[)4MZP_ M%LA-6&5@E,=[L5#C#C\@7O;TW .)XY,YO^\DF'2,&.9#KDJNB/[E4]Y0?RJ5 M0+$J:Z)HBFE>_R>-.8!T/CNJ&9+3O'MDLCU':%F$AJF2Y9''&#<'/IDS$!MQ M)FAJ+*L$N@$>X@ZCW36W+_8C1R(N*]8?]YRM]NH-HK-$0M?7CA>$;CO%3/#4 M)M^F0>Z,FHL$"SW6=KM?0N_F7E#V/#/FB;3L^7BH@Y+UG<)=PK/J%E7WI6\D ML3'A],N8\%F=?D"1E*/96/'XKK\B=9X<VKX,F4WI%<\1839 MW:C#!F:#K6L=.%+'9&/%9H]F(X?%" M\QK-\D#Z>GZ8:^ M6FM--F]'EZ]DL+V;ELY^5?J57NSI9,U#+VA8^T&I6 T6Z.*9/Q<=P0?B0=-I MN,$][_SYP;OR7[_CP^=O$UVC>[Y6((#B?G%M&^=6G"^!7V$9"[(T,3?HO(?T=JG]#+EKJ'H:,V[QG)CDU(2R MG16Z!Q%+$6\7R^HN77#3XL(_T=L5\OOQU5#VI_F>&A,*" MKB'"5\! [7\,2'L+85\S%SV'*FZ90O2OHH$&_!20 3;*GAP8+S"EYKD+8J!S MH X/=.'G@%RPTP[ AZM[,U70ER6X%3M%@&[\$J@;%?*>#+G!@O!$SPX$P(H* M&&C">4 F6 A[E?^*)5#QMU!P&A:<]@=L/2E_362,:!'1M3[6\"BH!@YU((1, MN)&U5Q?^QDB /=@!0QT((3EN8'QD_0>9$'O!.(<@.QKJ0 AI<1/G(UMPQ111 M:[,BZ%UFN7FL85445/(04F$;1R]2E[=#F#+KGEQR'R*ADH>0 ;NX>I%]H&,7 MB Y9@E=_X+5+]PH4*GP(F:^3K1?E;P1)D5B/2=P\PE2Q4.U#R'?=?+V(/T&K M8:(9D!DIEADV>V M K4BA&07Q-Z+(\-\P2+?N1\^X)D^6]<#GC@O!PT%H>Z$ MD 4_00DO'O631*LG-_\9)CV7,[5P\!.S8/QPL [$A=.GN7 *=R&$[+B1=2 N MG#W-A3.X"R%DR(VL?;HPT!]'8L(?+ _OK6"H R%DR V,?>J?7Z5&XD;P>U+L MXV@RH5("ZD0XB;.;N]?3H9@O0,Z%$@F5/YPDNIZK3]EON%2(_D.635/6>CS4 M@G#2:1?O8]\R+;J!N;-B6\%U ('*'4(&7;1SX(SYPWG*@HJ)G:_!RPH#$+?"ZLBJ?A1$ MZ0C,;H",;>XK61X96J!0M4-(2IULCZS\F%,2$[.!YJV>B@J":+WL=3BHYB&D MH':>1Q;\1F!C/-;3_7PUG=F6+4:SF6W4=N&A!H20@3;S]FO$4,H,BZ?:45,* M:DH(R2A4@V,/2CC.]!BY[IU.)^9U Y8AJ8*"2A]"(FKC>&2IW_&)0.:=*.-U M.N74OE>H%@@5/(2TT\'TR)KOQ5&O]@$$JG,(^68M.T\#R-4J7B VQ_9E(?5( MJ-XAY)\NKM[&[3EHW)X_<=P.(0^UG&Q\QI7\P_L#&&$G.<%*D&*X''-8B4%-"R'9![+TX\H'3 M3(LF\K6[PG*&6*!0!T)(;9UL_2R7+5:I;Z];Q=L970;82D!]""'/A7#WM&A0 M8?-N.W*/7R&%-A&Z[+"5@-H10A8,X>YMNX08Z(O6G+M7'QP H>*'D!H[F'K1 M?)PB2E]F4H0CIL8.I%\VO4BSF>@1\+?B#6FSV#+NTMQ2 >A!" MS@Q@[L>+U>/+#(J=DTXC:M#@%VB$XX*5LZ_WQL2Q6:%23 I8@H3%!!<>:D,( M^7,S[R,;,5(++'9G9GDP)GS7:I+F4E!30DBBH1KXN4SOO%W">97>PT'E#R== MKN/I9WM=-J4DOJ8<.?.!/1A4[G!RXQJ67M1^B=B=R)8J7M\('F-LGA[)[;D( MR,N %4 ="B=K?I(R?NYI/+YC-W_WKAQE*O^+&CH^YYT-9SFH4^$DU! =/,VO MY..>0)R\7-_B&19FP<<$K]1+W="=>[H%* ZU*X04_,FJU+CVHE.AJ9N\T]]N MOC$_S%\-T4?^ U!+ P04 " "J. )7[.7KY0,I !?OP $@ '1M,C,R M,C8U-&0Q7SAK+FAT;>U]^U/;R++P[U3Q/\S'N7LKJ=C&#R! LMPRQA 3P*QM M\MC:*DJ6QK8265+T\(.__NONF='#EHQA(9OD[#WWG&!I'CT]_>Z>T=O_FXTM M-N&>;SKV[UN54GF+<5MW#-,>_KX5!H/B_M;_'6UNO!T%T [:VO[O6Z,@< ^W MMZ?3:6E:*SG><+MR<'"P/<,V6Z+1X2RS7;5:K?.H MDV7:7_/'Q[=1T[YGF:FF^$1-4MM>&AK>&G&'9..];?$RU33(;+HKF@:JJ>D[ M.]7*ZU5PB!91AUE>VPK"#"ODGXX[%W'S(+M]W'0[\#3;'SC>6 M@#W&DW6*Y M6JSN)08I^EQ/#02_2T-G+KON9'&#?X KK5G/ ">E1K MJJ''![G#[FW#6]4P](M#37.CQ@/-[U-#^2(U*CSS'(O[F:WI3:JY$7C%8.YR M/QL4>+V-K[%/M5BN)="B.Z$=>//LMD.V/J4]XO5[>(2;EFP+\,_^]M8 86/WJ[+?Z%MV,>: Q' M+'(89_+[5L.Q VX'Q1XL;(OIXM?O6P&?!=N"E[>QW[8<]NW_*Q;9J?"&76EC?LAFQNP-:YW0'[?E:N/VIOM;]>2L7K^&?Q \5BRNV[MV?(L+O\U? M\*U:\ -&W=F)>CVF^^[.+0>:A=7 _S=MP.>\ 8CR-*ME&WSVGL]ORR#7]JM[ M>WNO'S+N06+<^IC;!OPW.+6TX>U LWS^@*%>O[[MMF__^NNJ=_4)!M-'YH[F MFH.!Y0-@\*!2"L:EP'%=S1YSSS,M"W'Y5UT/S D_=_K^7R?<#4Y-X IH;:(\ M8/OPUWO6<% YL!X?NY86P8M.N]U#;%@<88:_X/%?)XX>XL^6'8F1 M"Y NK8"/_1+ Z3]@17O'0$J+8&4.WC?,>;,#^86_WUK .QUR"IE-V ]'S'9L3B_-V2%R)/>0U>F7:1C<)L;'G]#P"O;! M,W7!T[.@@Q*V[K<'2/THU$%>,!M6"L-S\S"3IK>.8J)^NYT:]O$SI:A\ZXC( M/'/P[=2R<"[0 ]P#TX3[H@6JFT.?[ B8E)%Q<#@B73(.-+VH&+TT\XTM^1HE M^.];O@FTS(5PDU.E!Q?3^4[HJ=F@&>WQH5PF,XVE92K!JYIRPFKT-'IN&OAF M8'*/$?@\4S$W6N_3.[#8.9YN.W,^.9L+.'6,92C .O*"$^#HHW@):J3XW5(W MV+Z<3NK-(E@I -1#B<9\W)YZSCB>(_[K5@_] +3 C6T&?E/31Z##?-,/P%QM M#]HV)QYM#QJ6YOOUAC,>.W8W&3W#) MQWWN_6.;&.\+'R)_)%[(5P8 ,W,M4SSE_7<1K]RF6X%A@>U?GO!4D^5%_TLV#R.; M_Q91I9K\*V/2Q!*"]"9* 9MS:?O'7/-#CQ])X_00VJC!U*OT%#A:SOC"TLV= M0B*!&CUZCMBB7IH'K%^@NV7<8E^R$K7 \9;)[@$X6(0Q:]3$I"?<=L:F?=^T M]^-E<=ZL@=7[%!:6$"K-UH21*FQFY1B\W8;^\"_^YZVKG(FQY@U-^Y"!%[)U M]+__J>R5W[S==H]6-%KW=<*/ZH06+UYK0W)@DZZ,Z%D$/Y1ZOV'R0=\)P*:3 MSZ:F$8S042K_MI7JW7<\6)KH?6QI^E=6!5_*=RS3>,/D2S62>%^)WZ/W5?3- M._#M*LFU(Y+D_R96L)U:PB-0N*ZSIU! P['R&X9,7]0LM M;K?5OOH^<'S4_!&8J8$#_4]*C1*KEG=W#K[#W-]K;T_;G4OVUG,!AN,70_@/:L,3Z#EYH9'[[GQ\G")(QL+''E-9EM3&'79K+FK?W&&5>_.Z X?Q)HB M>OK[ECD+#@VTDJ'MR-#F#D-85+7 <-A<=OXG]W7GJ2A> M[),R^]+7P$&I>"E9;F:(;+7Y2WZ#5C2U>\' M R+M2MVQ+,WUP7I4?RT8JF22!YZ:8,*]P-0U2P$M[%+EZ+P-C 6C-M=NE9/4 MJK])&W;*S>$HP!$M(XVOW)+@\GGUX M-]U]K!C#_#-ZS0%W/6>"A)268VO !D*<6]H4)& N/P3&,H(E-408KB1\C$RD MQI25-=QWV*^]U'YA3@X6VN=>]N:,^Z>3'?>\NO?Q;XFD>!J, E6*M8/]2K[B M^#4074XANJ?-6C+8I1,!KL+ZZ[I^W+EJ?+LXW_E;:,^9%*SPW6*M7#[8WSM8 MM0GP/]ZC1<]B0W"L<\0_L2+:D Z8C![[ A:C;YC"G'0&;_N>2*692?9]F;VM MR^._81F K*:-]2''F+/I8^"1(84S@=X? [96J5/JEEAS[%K.G'L"C2Q-#NS* M*;U$"8LW=C"#9.0! E! 3(:I2 M=1>%F'KH"0&S^-CB@^CILI!YG1(R=#/MM=S MIG;V(C]\TR^^\"^O;]I_3XHN3;=U=.:!A3$U]=&J6 8M:J57($ MHZRS==+3LMZ:RUC<[UK6?E\[8*M:?YINOE'<:=COAN?G_M79ZR=BT-2D8(7M M[=?*JUAR70. 5-9]I+$F]EY(6-$-=#V@2]/5+,9G7 ^QD@P>@^;B?HZ"?=R< MJPCOD:L )#/$['((G7)(BA?Z] PGRFZ=_TA^&O]LYO'!DB2,Q#XY&0+LZS=50[J!0KU?T\D'^%..K: MP;8K)V!U%Q/UR%'?!P,O3AT/,"[C5![%'[@'Q"UD%A#\@(D0-\@/U*G,TOR MB9CO=PY7/6*2Y*A?0A^< M*>(%7R+ZV'[Q/1N8L(E#9OH@(@(.FVI@.L$WQZ$5:#9W0M^:,Q\VW1_,J:?L MX/0!.N&W0'M\D0@5$G' 9MAS5![4"XQ\9XH=,2ADHI?F'S[U-I@V.E2H('9- M^Z=Q;E1T8]^=+3 =*;B!-C:M^2'["! BE/ZR75.1XO"C9P:PA^@(A[;T*OT< MZ;T[[#;:K_G!Z?ZCTQ5]Q[$X;+<7\J2PS(2"=J.*N[$ZOIU4_,O(6*^F6@( MZTA"P-Q$N@QS_FRGNBLHE2UDQS I]J+RFC5..PP05H*&+_,LL02X6<9+\F%. MMT=M^8'<\JY#]5'0Z!+X')C=RMYO[9-?O3CM?/[Z[6_O-Q5R)S=\&0;!>_O? M9;?CV4$FB.F7M[JRHX&Z3NQV*@$:[?5.N21:_FC;K<*7UQY'OL+J=>%OAYIR+8YI/%T M@5N*."@Z>K;T+T970);&.E!8<]P#>]#-JC-!MMCW#+MP/18 TNGAD5!1_Z*/F(X%V(N1I0?G][YSS+"2-^??P(JGB6@(02J# MW=WYN.]8+S"D]7,AJ%9^<@1AM8H 4Y$.5Z(0V%\FL*8C$U[$HF*=D&4?EC;T M'!"QR%F.=\B\8?]%M;Q3J-;V"]7=W9<9$)#%\219 MWR>BQ5-)BU)D"2'U Q-BL(N+QL/5Y\>1&? ?0&?N/KG.C-HL'R>]O6N9@_.K*Z/[^6#T M.)I9<4!WI:[*4D(%YFH>FVA6R-G_E$MXMI*Y> ASM*J&\4>3*,^L>59NY_&. M-:W]Z>Y_.UV=I/N;VYDA\7^:[J8XJ-V MZD<6M#^@GW+R?#)W044;/?/3\-V?DUVC]O=V_0%>@6RJ'(/IR %S?BH>8B&* MIYL^F?@#K%>]SU&0HV@!> RJ-\?*%IVZ_$^E4MHM_P)2N_%,4GN!(.RYV1G7 M^*>S=N69"")#5G_\:78E2UB_?EYAO;!!GX_?W7SX>/&N73:?=(/^:1']E#71 M4K)/A0G]K&4ULHQCZZAE&YB"X*P_9SI5:T"OKP #IXK[A5(*TR=Q!8@:8D0$ M--(T&&UN@&!SL;Q"\YG!!Z8MCF2)M'9Y5U5=+.2TQ4'/&GN!"WW]AE+;JK%) MA[ERR?+CJNDNUDO6J X M/)US1.':.^_7=[H7[_M/GA?/@V2]?/@3$^N34_\_?#=,(E&6F4A+W!WS='?# M_"BXSRD6779?OZ.1LV+Z+$)!!+^!T;^%6*H!0 ALD\6^O/&Y2=(D656J&72U M1X>V[KO=1]VFM#2]Q[6OQ3X'=@<878(Y.>5>QHP(QD.G3-+?DY+>CT$IJ2+= M5832/\++A-E^J5QA;3*-FWAQAU]ZCC*8!T#U?+4XZP)11]4**E@49ZM[3 J; M&W2(="*NX:M4Z$:0:H'=<^5$@6E,';=GB5.]:-#O@S_X!AUO^K/R!I4_ZFOY MIJ$,6WKYLL#(9^;&YH9I@ZH'G5P?>EP47V&:]MK2\!0Q0.0- <078)MH8[)! M"LEAY>NHKQI?&"((CAJA&_8+K&7KI;Q%8!&Z09$CP)0S13_)#_N^:9B:1\7I M--J+],0P:KPD[-_SS*YFA3Z[, ?@">DF71^\>N9H4-4Y&G)S(VD/40U% :'Z M I:1*J87%?>:/'?ML:EF3@ R %CG7J"96-T,)J H9//!70:I!+A!-N&F74C@ M!Y!F60P-2:X,.?05 V=S(UK6BR7DQ^NG/E%+/_0FY@3-/.PB9\%MO _' I&I MP>1QIV0:FA>N,G +J MZ*MX$E;ST&&0;A%<>'%PWBFQ6JU6K.X=5&K[+S7;*C(I_"BGQW*=ZIP38W\+97([3$Z1T@K1'8#[C$].U0 M!7RK 0\-Y?4. 5ZW!Q3F]$FF1,>&)N"_ (3 EYX8,J)PGDMN3Q?>>: Z_&?M ME"Z=+DN>C"+^W]Q8BQP*L6@58@_0/97G5T#T@7#Q ?"!YXQC3CIU'(-(^,0+ MAZQNC&$:Q08"%TKUG)[48Q(Q<41Y]3W1 <-+ -EQ1&BXWW@_&CK_"S*:73<[ MK781+#$=UHAQ:RL/1#S"0)#.,=."&(V3Y'0M(,26Y?0GM!.:\I M"40U;30H4V/B16MX48S'P4@BZPU4Z$0S+9'[!*.%[$*PE3 D[P@QWL*=M\$P M!(.?PY+!XM,H39!4@P%;OAV\Q#!UE;MF<8HT?BVT>>CBW84^C9QH#7HI,DVE M>O$E,](%W=:R\:,$CM(PRNZ1W=="94DT0\W%O;&/ 4]P2?IA0!%0E2\1IC(; M:1,AOL=EH<)UX7;2)LSD@3ABA6OH3ODTLALC6P!?/XE.W]Q85NH].0$LS7:F MP*=XD)Y4L@N&JXGWF(-O!TROQ0!%-H(;XO_89"V#?0,NJ:=1GH2FE,R$VQ2!':]^8FH,@8]% M &#@2IM VXFI<]J1S0W<$LSH:/Y7+K(T>! %0::K65Q+!1^D$^JX@3F&5PK% MCL\Q=P0;XL-C"VM=@M# W3 QLN/@MNB<&W'6)^4VPD@!'K M)6('NC#R@,QA M?HY"#(8AH7H-D')686/'0PT4P.ZA.P:$IDO2$8AC>-> B7=3)<#T:76H^I9- M3X)!2B%4,1@*@2FM 2X;&:W$CC7$N]2%T@PF[VH JT.&31C>(D#B3*B.:*IY MAEKZ3KF(%4%BMR6F8'%#;N,'!'@*]W)=(-QQ8;3'J'Q ;.=M!"TPBV]*,6@N M4!PAE 2M\KX$8JL2#TMXDL-L;B1A)==N&5ZB8(*&(#3O!/G0(@#!B,PW;.1, M^01OD1$:A2#!5D3]* O(Z2'+.@4:V08HZD2HA08=XW?G L?&,(#'DV$O&0\@ M@+C+2<;B#D;4@>$PQ_,+*4\#D*SB/Y++AJ&%WUB I87 _B+D@)%)#Y3Q6-S\ MC+:*8%Y4UAXAA&++T@8;:W-FCEV\"-=QN2?/BP*U1B2(5A7HMCK*MD'HD3,- M# Z@*M9+2>\$M6E@^.!52M ?K^5&)X>Y#IH,N)F88"7)IHD+583B#OLJ1+(H M220]P58MR"AJ2%)&23+D*; <+?,KMXB.'1UX%]3_W,%=@JW>+3#$.R)6[>,: M=/*+N4YK9P+62&15_TUD/6,BZ^>@DXR +4AKT!,@<2S'I8@&BGF2XR,.@L'! M8\P@Q, QT#S=)'96]LV[1B,.S4%F* P?@"QEBP+-E.GP_*#$LS'8Z%F5(4E*AKPIH N7NG M.@DOHZ]T,BD"82V0UP$&'T]XM+&GN*37?^@2"+P8\&@A0BN,EGP72^ISD-K8*C>(&7XXM8O+"A9'IP,:TETISX1G2!EIDA>E:W MTN$^$019$22MK_9C#YD8J-B4#3(A9E%KEVIOU$?R4O"Y84S'.DW.D&+X> M6]>)CR*SGU4"Y"0:\Q*JFQLK*4](#EDO()-LJU)X:KINLZ'X5] C^@V,R"?. M86Z[B8R<9# U%5G8D09RY+ + TBA92 H9C^4C*;RT7+$5/8Y([. /I@O+J.2 M<3ZZ.-69F=*9Q4&(PV4(-E$](1)_.+*:=-'0S\NZB5PF^1] < %VU7QR8"BN MY^NP(%&0L0+?!>PS!:L#_Y7X43F49)Z2/%F,78J4C&9%\LR/L[L"ER;>_!-% M+!7DFQLI::0"9)77J1SL6(OH8[T\CY**V#F%12W>/4M*WWX$BLH U](*R/1E M[%,',QUM%<[ 8P5Y9OHC;F3M?#I]FR !ED .F(]T-BS8B!:W0)8??@] B"T![P(:@;ST7 MR3N1(X"U)U,&%"T+G!39T661!)@A/W0$\ A!D90&@ 9=DQ7,<\'8,CZ.'CM8 M*71H8DG#B1*4A!-NY.>QLY (%LZZ6"3FDPEU2L[HCFORB!#7H^AX@@@;0FIN M;J2Q,1=4'XS ]QB*YV#WK$[ZI+(]C11T"[-%J-_]%UBCQ^CJ[)_ +[C6/!GW MD?'E;D)._*PV0H)1TG5RDK],+YE"$L3@>+ZP5A=O$L?(GKAX#4G- V<"'D2* M3"6H4 HJ5"*9*F7+R68'Z*>QL\ M$-HL*9,\/M2\R+3&(C 9*E72Q%]4G"F5G[.H"+]">DBDJI$66XMJ%7_!U$K< M$Y[5:74-F:"Y;K$2^7*H?ST3R$A#)9(AS1,5JZ)WK4S:N$RZ016=90-3M^T0 M=%^ZND2,4BGCU<92XPY,'T.V^$4])@Z\G' ].654*9L-X*7FZ2/1%!I1I+16 MB%3((Y/#Z!H!R= 6Y!%I;%-1/D7=9ZT2;L!&8SQTXT?^^0,3Q!2Q%Z/**?H@ M6JG<-*I0',BS0TESD2!NB'"]"79N>VH#H8U,-[T).QGX+*5\HS0?*/TY'3G( M1AG2()8$&3( 5'2>Z:4RE"LMHP=( 4I=2'\D ^F;&ZLHX1X!LN"_I,4J3!MZ MPTSC3$!A>G&IR/I5: ES PQ//D$;*K8$4B[4\I8BLW-;V&-@G#GC1"ROH,PU MXN 'V&O/7V3XG0Y!+:8$:O^F!)XC)?#=@B(K>50[^0KLYW(5W=RX:O?8<;,)K:^O.^T/\+;=82>M;O3S^#/KO6O2 M/L$;'+,-OSNLTSR[N:CWVIW/K'[3>]>&63ZS*V@"PU*S^.EUO=N%D6ZNVUN,SP7#2_..& M_A9]6E?XJ?1ZKP7#-]I7O7KK*EIDB4#I-*\[S2Z@133JM:D?MNW4 ?X6 ,P M-Y>MJ_H%@G+:O.HVGW[WG\E=/!65*,4+Q_F*+!';7C^GKYB5(/W/:1/_LR6J M;-/%XA2=BTU)JA@7/%+P =EYTD M:W:R4E'*L:'S_SSK2--"%+%, >2+@ M\,DM%9^B*:C]DT_1)UAXA(ES]6QS0SY$+:S:D9J&Y6(V'38%BP@5JLGUYO@- MFTGB@Z<3S3-EO8^J:8I7HM::6!NN"(:5GTB%_02GXXOP(62<0XR;[$+Z6>ZG MK#L2A4!>(DF.@#AH B2)15T2 ^!B*7,"E:O/7$1<)$$2S"!+]U+4FN>,)BT( M1>6)V [(!##GXH)PC0HA@R1J<&0-K!HL,^4>F2M@$1- PMF7!52%Q<(PS_2_ MRC)S6_(^\N9/ILE72L!+RHJ)^C9@/#P (-TFB3&!&J+;1.$(Y05$-7GT\1., MLPA_%Q,>DN:1I#PT%RW)=D38^2R;S/[V0Y#&N).9;6T.3)V0?@&"/;8ZF]%G]4*W&8 M5^:RUC]2NA"R4^?W5*>EA*U<2"KVD<:B2-:FCR"+!GC4;!R.@3C]$1/1I\0A M!R1BX'TLX_[ZBDJ#ACLG1H M9!'OH)]>3)Z*$H#V)YB8!/TGOVV"*X4>X,,79=WK'1 M?>Y!A,+PF >YA1W M(6YNK+BPMI .^1C<-X>V."WMD[S#^\0 %39=HH>^KKBY#8-2E&;%^O>H+'QE M)"TN7!$23GJU5'DKSZ,**D-RT%R3*""J+Y$8BF)E4C!$U;0(3<+2R0( R&:2 M8%"P.W4!NI M."RIZ(*J3XXL!=WTP/_%VX[H_"=6!Y/@'J(^]/!N20F>H+'4 M_BT1!T*1 B/!!N ZA[:,;7)#)N!)QFNV $60-A7X@4BUJ*29U'+B?'P21$HS M#.C$PJK-(9)-RR]QG%HM V2V$ZJOZ\#LHFI;GZ]"..[KHB$1R5!1; $/S)= M/)8LBJ]1M"D%2+6*JGED6"+SSQXFY W3]T(WB XPR%I[,H_BFF]8B (6YIBE M""4,*-@IJ<0"4])*G)^0-IU,8('?$I@!599H0_1B@C@>(VU11<7WE'JIYIG& M.,*8W"ZM;UH8H J<*,)#G:WX POW9!XD%XJ+&VEX-;Y*',"0:D- K(SI]L9" M?#486,1 NG37)B%7X"D6V)Z#BF% MK,--5(Z$]8-B_$D&3A8"[1*M0HNCZ%0%1(XXQ9,\/2$7)XXZKTH:I L[Q!$; MT9E3O5""TN0JA5N 0&?!C"=!QNH<=,0&1+D%1 /'@L=DV#!IVJ/U%/!HF3G. M7=JXH..FPLN82]6K6:!:DMAP7'0U0EN96S,0J"L]8G!F);:E)RH&EA;N('&L M+'WDQ\]3_LG3$A*"B$H=/U@JG\SEG4FNM:;6O>A+]T$$#S M0%0QXCGB]KBT?,-QQ/=UZ?J]A7"!LLL7*\3B81.&5=(>$]XP<(,28S+CD^U> M83):W#&H,HY@J!,"\=][RLF2M:-H$,0?5%-7AZ" /A4.C_+5U='@0)[,%1?5 M9.=^!>A9.6Q1OH.\,'00 !1UN#G*NP(?&>V[J*CX!W8CU\LH[?R;4?II,TKW MA$4SW$U!^!BY5\2?$L_R^]>J."W*#^4P>=(H%&5U,MX@PU))P9P5:@!)?D^L M0:FUW% #WF>2&SD$X::!%V=;\T0IIR'/,XIPXE@S>&ESHP,>-U7FX2UL=)K!0I51!^X3E4ZH327I9ID MALL@'A?MXP]GBS-U(I)'$4^ZG96N4HAO6<715X97XZA@(HB&8-E\BD(\2@P6 MTC''0N3*3&&:$KMZ['+9XFJ'8LUT/;4?>B+,1Y3&S4#=<9VPN](G<35]9/*) ML(^25L./+:@I:W/E,/K**2[JUZCONS^BS,0M$D#$>-&U#A?+^Q" #/"J]75(&60(> MRG6IK$<2*DI\F'[Z [IH26&MHF?J,CX*_=\ VRH32\@T>4]!=+9";"IM'@6X M^W-"@BC^8J9=6,;)E/!+4*6&$4/$F, ,H8?W4@ .+ ?=!H!(2%)R&2A;!3Q* M:%6GUA.YON@^%-0I:"%R-W6^3)P\4;49ZHH-@6VZ*BTJCI.77*MBQ.S[^']L M@;:&Y;G[K^7Y,UF>BQ\VZ1]U6V=7]=Y-I_EC*Z>MH^O$A:E9_+; 7*FO=LOO M4\@BXH6K\0T\ $26KR'RIZ*45E::8]Q;9&/1&.ES.HLLDQHD064#E$\AWGA+ MP\7Q]V?D\!_C ]AY7],1?)7X0%;VMWA@/+S?_O>M&I'C/25>@DAS/M?U!! D M&B1G2 QQ@M&00WEP65:$B\-CZWUD2 %U/#_,@Z.ZE2-&^^M]$WKK:-O?9HT1 MJ$^0=FAL-_ ZM"F?/QYUJJ'Z(#G>R+_JVTKJJ]3W-<,+$HI(OD!:MC/U-#?^ MZ/EO6_0)ZD4\I6?8J4*SIUUK)L39#^DK90L HA?0 /]E #)('6]IBY,8P@EX MID\9_4,6P-X;UA;!Q4-VH?G!CV,0?#_MO-UWC#GNX?8H&%M':81U.:R&")G- MC-D;UCJA/V[+^\>W=!9$E",1<-2/G\\_?+TZ;=>_-/_H]%_5![M?_,OR^]>S M\R]^];5[_'GXQZRQ]_Y\7WOGWWV]. F^PNHFY^?;WSX$'UYU_W2_VKW:NXE] MUYQW#\XOSZ_UX<>3_MW JEQ]=H)OM:EY=E-]?WS\23NMG;8.KL\&9FW6JI;O MAE^"G8FN7UR.[/*9$1[OSH-)IQ%TJN/9G=.PI[-FWQU-=^[*?]:^7K[J?@KJ M%V6GZM_T?/?CJ+$W&ADG?'[=:7RZ_O;>O#N]JEI==V>D.?VS;M#8KWT^K^W7 MY_:7][V[WLVG>:?Z8?RYYX1?*SNO;*L\O7PW^'RLOVZT3UNS_H?S72M\]<6: M6=JWO4N+!Y\ZU8OWWX+^?FWO4OO$[\[#W9G_X>/9^;36Z8;^W:#JF)->XZ;_ MZ<+@M0^['S2M/7'?>\=G'SY>#';.O]Y]+O]Q]^',*;^[/-?:9Y<')SNS=]WC M[3\^?[O>V?VC7OVCX]6/3WL[G>,O5KG=,O?#QJ=):#>/^>==_=MUX]WDS]VN MT>F\/OGCYE4X:;ZZVYWL'W_4CBQ??\?4$L! A0#% @ JC@"5^>E M@,CB P B@X !$ ( ! &UT86,M,C R,S X,#(N>'-D M4$L! A0#% @ JC@"5PT-9=LK"0 \6L !4 ( !$00 M &UT86,M,C R,S X,#)?9&5F+GAM;%!+ 0(4 Q0 ( *HX E>>]CURM P M *25 5 " 6\- !M=&%C+3(P,C,P.# R7VQA8BYX;6Q0 M2P$"% ,4 " "J. )7&UL4$L! A0#% @ JC@"5^SEZ^4#*0 M7[\ !( ( !!2, '1M,C,R,C8U-&0Q7SAK+FAT;5!+!08 1 !0 % $@! X3 ! end